- Home
- IGC vs KLRS Comparison
IGC vs KLRS Comparison
Compare IGC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- KLRS
- Stock Information
- Founded
- IGC 2005
- KLRS 2019
- Country
- IGC United States
- KLRS United States
- Employees
- IGC N/A
- KLRS N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGC Health Care
- KLRS Health Care
- Exchange
- IGC Nasdaq
- KLRS Nasdaq
- Market Cap
- IGC 39.8M
- KLRS 46.0M
- IPO Year
- IGC N/A
- KLRS N/A
- Fundamental
- Price
- IGC $0.42
- KLRS $4.61
- Analyst Decision
- IGC Strong Buy
- KLRS Strong Buy
- Analyst Count
- IGC 2
- KLRS 2
- Target Price
- IGC $4.00
- KLRS $23.00
- AVG Volume (30 Days)
- IGC 1.4M
- KLRS 670.7K
- Earning Date
- IGC 08-14-2025
- KLRS 08-13-2025
- Dividend Yield
- IGC N/A
- KLRS N/A
- EPS Growth
- IGC N/A
- KLRS N/A
- EPS
- IGC N/A
- KLRS N/A
- Revenue
- IGC $1,327,000.00
- KLRS N/A
- Revenue This Year
- IGC $15.26
- KLRS N/A
- Revenue Next Year
- IGC $3.41
- KLRS N/A
- P/E Ratio
- IGC N/A
- KLRS N/A
- Revenue Growth
- IGC 24.95
- KLRS N/A
- 52 Week Low
- IGC $0.25
- KLRS $2.14
- 52 Week High
- IGC $0.50
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- IGC 55.05
- KLRS 82.39
- Support Level
- IGC $0.39
- KLRS $2.37
- Resistance Level
- IGC $0.47
- KLRS $4.90
- Average True Range (ATR)
- IGC 0.04
- KLRS 0.60
- MACD
- IGC 0.00
- KLRS 0.20
- Stochastic Oscillator
- IGC 43.67
- KLRS 46.42
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.